Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors| Amgen

Amgen Announces Appointment of Charles M. Holley Jr. to Board of Directors

THOUSAND OAKS, Calif., Feb. 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of Charles M. Holley Jr. to the Amgen Board of Directors. Mr. Holley will serve as a member of the Audit Committee and the Corporate Responsibility and Compliance Committee of the Board. Following the appointment of Mr. Holley, the Board will comprise 15 directors, 14 of whom are independent.

"Charles Holley brings deep financial and organizational experience from one of the world's largest and most successful companies," said Robert A. Bradway, chairman and chief executive officer of Amgen. "We welcome Charles to Amgen's Board as we work to shape an exciting future."

Mr. Holley, 60, is the former Executive Vice President and Chief Financial Officer for Wal-Mart Stores, Inc. ("Walmart") where he served from 2010 to 2015 and as Executive Vice President between Jan. 1, 2016, and Jan. 31, 2016. Prior to this, Mr. Holley served as Executive Vice President, Finance and Treasurer of Walmart from 2007 to 2010.  From 2005 through 2006, he served as Senior Vice President. Prior to that, Mr. Holley was Senior Vice President and Controller from 2003 to 2005. Mr. Holley served in various roles in Wal-Mart International from 1994 through 2002. Prior to this, Mr. Holley served in various roles at Tandy Corporation. He spent more than ten years with Ernst & Young LLP. Mr. Holley is an Independent Senior Advisor, U.S. CFO Program, Deloitte LLP, a privately-held provider of audit, consulting, tax, and advisory services. 

Mr. Holley serves on the Dean's Advisory Board for the McCombs School of Business at the University of Texas at Austin and the University of Texas Presidents' Development Board

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

For more information, visit and follow us on

CONTACT: Amgen, Thousand Oaks
Kristen Davis, 805-447-3008 (media)
Trish Hawkins, 805-447-5631 (media)
Arvind Sood, 805-447-1060 (investors)


To view the original version on PR Newswire, visit: